Surface Oncology, Inc. (SURF) Social Stream



Surface Oncology, Inc. (SURF): $7.23

-0.32 (-4.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About SURF

$SURF I felt really confident with this stock + company.
Until the 300 Mio shelf ATM.

Maybe this is necessary to prevent a takeover. I don’t see any reasonable use for this money today.
They were not in need for money and they sold ~ 2 Mio shares last quarter.
I really don’t understand the last actions with „investing“ 80 Mio into bonds.

With SRF 388 in NSCLC (possible two trials! Mono and combo), SRF 617 in prostate and SRF 813 IND I See many good reasons to invest the money.

We have a ODD in HCC and a ODD in pancreatic cancer. It is not mentioned anywhere on the new slide deck.

The phase 2 data in mono hcc could lead to accelerated approval or to a pivotal phase 2/3 trial and any approval would lead to a Priority Voucher which is 100 Mio $ worth.

In my opinion the business plan was to buy a solid pipeline with several assets and to sell it in quite early stages . I don’t know why, but the BoD changed their mind.
Surface can be worth up to 8 bn dollars with approved 388 & 617
Jalu06, published August 10, 2021

What Else are SURF Traders Talking About?


Other tickers frequently mentioned alongside SURF is .

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5788 seconds.